X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Nicole Longo

Nicole Longo Nicole is director of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.

Recent Posts

PhRMA submits comments on FDA’s proposed rule on drug importation

By Nicole Longo  |    March 10, 2020
Yesterday, PhRMA submitted comments in response to the Food and Drug Administration’s proposed rule, “Importation of Prescription Drugs.” As PhRMA President and CEO Stephen J. Ubl stated when the...   Read More

Three reasons the Administration should abandon its International Pricing Index proposal

By Nicole Longo  |    January 31, 2020
According to the Council of Economic Advisers, “Heavy-handed government intervention may reduce drug prices in the short term, but these savings are not worth the long-term cost of American...   Read More

Drug importation: An old idea that is still a bad idea

By Nicole Longo  |    January 28, 2020
2020 may have kicked off a new decade, but policymakers are stuck in the past, focusing on old, dangerous ideas like drug importation. For all the same reasons we’ve discussed before, drug...   Read More

New GAO report: Some hospitals participating in 340B may not be eligible for the program

By Nicole Longo  |    January 14, 2020
The Government Accountability Office (GAO) released a new report on 340B hospital eligibility compliance and made a number of alarming observations that underscore the need for more accountability...   Read More

New poll: 76% of voters concerned Speaker Pelosi’s plan would result in fewer new medicines

By Nicole Longo  |    December 5, 2019
The House of Representatives has spent much of this fall focused on Speaker Pelosi’s drug pricing bill, H.R.3, but a recent survey of nearly 2,000 registered voters confirms that H.R.3 is not the...   Read More

Fact Check: How hospitals continue to drive health care spending

By Nicole Longo  |    August 21, 2019
There is a lot of talk about health care costs in the United States that is mostly centered on prescription medicine spending, overlooking the largest share of U.S. health care spending – hospital...   Read More

340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients

By Nicole Longo  |    August 20, 2019
Congress created the 340B program to help safety-net providers, like federally-funded safety net clinics, access discounts on prescription medicines for vulnerable or uninsured patients....   Read More

New analysis: Government intervention in Part B threatens patient access to medicines

By Nicole Longo  |    August 19, 2019
A new analysis from Avalere looked at how access to medicines in Part B may be impacted if the government only covered a certain list of medicines, an approach known as applying a national...   Read More

Three things to know about the Part D GAO report

By Nicole Longo  |    August 16, 2019
The Government Accountability Office (GAO) recently released a new report looking at Medicare Part D and the role of Pharmacy Benefit Managers (PBMs) in the program. While the report provides a...   Read More

What they’re saying: Safety is top concern for recent drug importation proposal

By Nicole Longo  |    August 8, 2019
Last week, the U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) released their “Safe Importation Action Plan,” which would allow importation of...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates